- cholesterol

The FDA has approved alirocumab, an injectable cholesterol-lowering medication and the first commercially available proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor. Alirocumab (Praluent, Regeneron Pharmaceuticals and Sanofi Aventis) is approved as an adjunct to diet and statins to treat patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease who have not been able to lower their low-density lipoprotein (LDL) cholesterol.

 - HeartDNA

New research is revealing the level at which radiation exposure received during CT scanning damages DNA.

 - aspirin

More than 70 percent of adults with atherosclerotic cardiovascular disease (ASCVD) in 2013 took aspirin daily or every other day to reduce the risk for myocardial infarction, ischemic stroke and fatal coronary events, according to a Centers for Disease Control and Prevention (CDC) report.

 - brain sketch

A systematic review of randomized, controlled trials and prospective cohort studies found little evidence to suggest older adults experience long-term cognitive decline following cardiovascular procedures. However, better evidence is needed.

 - deal

St. Jude Medical agreed to acquire Thoratec for approximately $3.4 billion to expand its heart failure business. When the deal is finalized, Thoratec shareholders will receive $63.50 per share in cash, a 10 percent increase over Thoratec’s closing price the day before the announcement.